Posted from: Thursday, May 05, 2016 - 12:13 PM - Present

FDA Rescinded Advicor

April 18, 2016 – The FDA revoked its approval for two drugs, Simcor® and Advicor® that combine a statin with another cholesterol-lowering drug. In a Federal Register report, the FDA stated that reducing triglycerides or increasing high-density lipoprotein cholesterol (HDL-C) has not been proven to decrease cardiovascular risk. These drugs have not been distributed since the end of 2015. AbbVie voluntarily stopped production in 2015.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Monday, April 24, 2017 - 05:50 PM.